174 related articles for article (PubMed ID: 1703909)
1. [Recombinant human erythropoietin (rh-EPO) in chronic, dialysis-dependent renal failure: effects on macro- and microcirculation and hematologic parameters].
Köhler M; Mörsdorf S; Jung F; Braun B; Waldhausen P; Pindur G; Weber U; Bosslet R; Bambauer R; Jutzler GA
Beitr Infusionsther; 1990; 26():89-95. PubMed ID: 1703909
[TBL] [Abstract][Full Text] [Related]
2. [Effect of recombinant human erythropoietin (rHu-EPO) on anemia and selected biochemical parameters in patients in the pre-dialysis period].
Sułowicz W; Drozdz M; Hanicki Z; Kraśniak A; Kuźniewski M
Przegl Lek; 1992; 49(1-2):50-3. PubMed ID: 1455007
[TBL] [Abstract][Full Text] [Related]
3. [Human recombinant erythropoietin (rH-EPO) in chronic hemodialysis patients].
Jalil R; Vaccarezza A; Jara A; Lira P; Vial S; Serrano V
Rev Med Chil; 1990 Jun; 118(6):629-34. PubMed ID: 1775783
[TBL] [Abstract][Full Text] [Related]
4. [Effect of erythropoietin therapy on alpha receptor density in chronic dialysis patients].
Fritschka E; Neumayer HH; Seddighi S; Distler A; Philipp T
Med Klin (Munich); 1991 Jul; 86(7):353-9. PubMed ID: 1656181
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of indicators of erythropoiesis stimulated by recombinant human erythropoietin in renal anemia.
Schmidt G; Stamminger G; Daniel A; Gross J; Syllm-Rapoport I; Lun A; Zoellner K
Biomed Biochim Acta; 1990; 49(2-3):S275-9. PubMed ID: 2386517
[TBL] [Abstract][Full Text] [Related]
6. [Effect of recombinant human erythropoietin--rHu-EPO on the metabolism of children treated by long-term hemodialysis].
Pietrzyk JA; Smolnik T; Szymowska M; Dyras P; Lenik J
Przegl Lek; 1992; 49(1-2):55-60. PubMed ID: 1455008
[TBL] [Abstract][Full Text] [Related]
7. [Erythropoietin--the first hematologic hormone in clinical use].
Rhyner K
Schweiz Med Wochenschr; 1988 Mar; 118(11):375-80. PubMed ID: 3287601
[TBL] [Abstract][Full Text] [Related]
8. Does additional treatment with fish oil mitigate the side effects of recombinant human erythropoietin in dialysis patients?
de Fijter CW; Popp-Snijders C; Oe LP; Tran DD; van der Meulen J; Donker AJ
Haematologica; 1995; 80(4):332-4. PubMed ID: 7590502
[TBL] [Abstract][Full Text] [Related]
9. [Effect of using recombinant human erythropoietin on the effectiveness of hemodialysis in children with terminal renal failure].
Pietrzyk JA; Dyras P; Smolnik T; Szymowska M
Przegl Lek; 1992; 49(1-2):61-5. PubMed ID: 1280842
[TBL] [Abstract][Full Text] [Related]
10. Clinical efficacy of recombinant human erythropoietin in hemodialysis patients.
Mohini R
Semin Nephrol; 1989 Mar; 9(1 Suppl 1):16-21. PubMed ID: 2648516
[TBL] [Abstract][Full Text] [Related]
11. The use of recombinant human erythropoietin (EPO) to correct the anemia of end-stage renal disease: a progress report.
Adamson W; Egrie JC; Browne JK; Downing MR; Eschbach W
Behring Inst Mitt; 1988 Aug; (83):188-92. PubMed ID: 3071336
[TBL] [Abstract][Full Text] [Related]
12. Blood rheology and 2,3-diphosphoglycerate levels after erythropoietin treatment.
Crowley JP; Chazan JA; Metzger JB; Pono L; Valeri CR
Ann Clin Lab Sci; 1993; 23(1):24-32. PubMed ID: 8430997
[TBL] [Abstract][Full Text] [Related]
13. [Recombinant human erythropoietin: 18 months of continuous use in substitution hemodialysis].
Canaud B; Polito-Bouloux C; Rivory JP; Donnadieu P; Taib J; Florence P; Mion C
Nephrologie; 1990; 11(1):5-10. PubMed ID: 2374643
[TBL] [Abstract][Full Text] [Related]
14. [Treatment of anemia in patients after long term hemodialysis with human recombinant erythropoietin].
Boratyńska M; Mazanowska O; Szewczyk Z
Pol Merkur Lekarski; 1996 Nov; 1(5):329-31. PubMed ID: 9273209
[TBL] [Abstract][Full Text] [Related]
15. Recombinant human erythropoietin resistance in hemodialysis. Effects of paired filtration dialysis.
Carozzi S; Nasini MG; Santoni O; Tirotta A; Sanna A
ASAIO J; 1997; 43(5):M535-8. PubMed ID: 9360100
[TBL] [Abstract][Full Text] [Related]
16. High doses of recombinant human erythropoietin fail to accelerate platelet reconstitution in allogeneic bone marrow transplantation. Results of a pilot study.
Vannucchi AM; Bosi A; Linari S; Guidi S; Longo G; Lombardini L; Mariani MP; Saccardi R; Laszlo D; Rossi Ferrini P
Haematologica; 1997; 82(1):53-6. PubMed ID: 9107083
[TBL] [Abstract][Full Text] [Related]
17. The rate of increase in hematocrit, humoral vasoactive substances and blood pressure changes in hemodialysis patients treated with recombinant human erythropoietin or blood transfusion.
Ono K; Hisasue Y
Clin Nephrol; 1992 Jan; 37(1):23-7. PubMed ID: 1531789
[TBL] [Abstract][Full Text] [Related]
18. Serum erythropoietin levels and their correlation with the erythropoietic system in hemodialysis patients and renal allograft recipients.
Khosroshahi HT; Shoja MM; Tubbs RS; Estakhri R; Ardalan MR
Transplant Proc; 2007 May; 39(4):1051-3. PubMed ID: 17524889
[TBL] [Abstract][Full Text] [Related]
19. [Effect of recombinant human erythropoietin administration on cardiovascular system in patient with chronic renal failure: an analysis of the blood pressure upward].
Satoh K; Ikeda Y; Kurokawa S; Kamata K; Masuda T; Kikawada R; Marumo F
Kokyu To Junkan; 1989 Mar; 37(3):313-9. PubMed ID: 2734509
[TBL] [Abstract][Full Text] [Related]
20. Long-term erythropoietin therapy does not affect metalloproteinases and their inhibitor levels, oxidative stress and inflammation in hemodialyzed patients.
Pawlak K; Pawlak D; Mysliwiec M
Am J Nephrol; 2007; 27(3):221-5. PubMed ID: 17384500
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
